How Does Pharma Learn To Speak “Patient”?

whitePaper | November 18, 2022

Research by McKinsey on the operational practices of more than 25 global pharmaceutical manufacturers found that the top companies are more than twice as productive as their counterparts.

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

whitePaper | May 26, 2022

The medical device and pharmaceutical industries each share in a mission to improve health outcomes, from prevention to intervention. As a result of this shared mission, integration and overlap between these two industries has been taking place for decades.

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).